{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:57:25Z","timestamp":1789412245535,"version":"build-2803163510"},"reference-count":37,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0211","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:12:21Z","timestamp":1774339941000},"source":"Crossref","is-referenced-by-count":1,"title":["cme"],"prefix":"10.3238","author":[{"given":"Lars","family":"Kellert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz F.","family":"Sinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"H\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Linnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"key":"10.3238\/arztebl.m2025.0211_ref1","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al.: 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45: 3314–414."},{"key":"10.3238\/arztebl.m2025.0211_ref2","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al.: [2021 ESC\/EACTS Guidelines for the management of valvular heart disease]. G Ital Cardiol (Rome) 2022; 23: e1–e75."},{"key":"10.3238\/arztebl.m2025.0211_ref3","doi-asserted-by":"crossref","unstructured":"Douketis JD, Spyropoulos AC: Perioperative management of patients taking direct oral anticoagulants: A review. JAMA 2024; 332: 825–34.","DOI":"10.1001\/jama.2024.12708"},{"key":"10.3238\/arztebl.m2025.0211_ref4","unstructured":"Douketis JD, Spyropoulos AC, Duncan J, et al.: Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179: 1469–78."},{"key":"10.3238\/arztebl.m2025.0211_ref5","doi-asserted-by":"crossref","unstructured":"Healey JS, Eikelboom J, Douketis J, et al.: Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 2012; 126: 343–8.","DOI":"10.1161\/CIRCULATIONAHA.111.090464"},{"key":"10.3238\/arztebl.m2025.0211_ref6","doi-asserted-by":"crossref","unstructured":"Sherwood MW, Douketis JD, Patel MR, et al.: Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 129: 1850–9.","DOI":"10.1161\/CIRCULATIONAHA.113.005754"},{"key":"10.3238\/arztebl.m2025.0211_ref7","doi-asserted-by":"crossref","unstructured":"Mendoza PA, Narula S, McIntyre WF, et al.: Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: A systematic review. Pacing Clin Electrophysiol 2020; 43: 1373–81.","DOI":"10.1111\/pace.14091"},{"key":"10.3238\/arztebl.m2025.0211_ref8","doi-asserted-by":"crossref","unstructured":"Tafur AJ, Clark NP, Spyropoulos AC, et al.: Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study. J Am Heart Assoc 2020; 9: e017316.","DOI":"10.1161\/JAHA.120.017316"},{"key":"10.3238\/arztebl.m2025.0211_ref9","doi-asserted-by":"crossref","unstructured":"Douketis JD, Spyropoulos AC, Kaatz S, et al.: Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015; 373: 823–33.","DOI":"10.1056\/NEJMoa1501035"},{"key":"10.3238\/arztebl.m2025.0211_ref10","doi-asserted-by":"crossref","unstructured":"Kovacs MJ, Wells PS, Anderson DR, et al.: Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): Double blind randomised controlled trial. BMJ 2021; 373: n1205.","DOI":"10.1136\/bmj.n1205"},{"key":"10.3238\/arztebl.m2025.0211_ref11","doi-asserted-by":"crossref","unstructured":"Praz F, Borger MA, Lanz J, et al.: 2025 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2025; 46:4635–36.","DOI":"10.1093\/ejcts\/ezaf393"},{"key":"10.3238\/arztebl.m2025.0211_ref12","doi-asserted-by":"crossref","unstructured":"Douketis JD, Spyropoulos AC, Murad MH, et al.: Perioperative management of antithrombotic therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest 2022; 162: e207–e43.","DOI":"10.1016\/j.chest.2022.07.025"},{"key":"10.3238\/arztebl.m2025.0211_ref13","doi-asserted-by":"crossref","unstructured":"Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W: Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381–91.","DOI":"10.1161\/CIRCULATIONAHA.112.115410"},{"key":"10.3238\/arztebl.m2025.0211_ref14","doi-asserted-by":"crossref","unstructured":"Kirchhof P, Camm AJ, Goette A, et al.: Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383: 1305–16.","DOI":"10.1056\/NEJMoa2019422"},{"key":"10.3238\/arztebl.m2025.0211_ref15","doi-asserted-by":"crossref","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al.: 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43: 561–632.","DOI":"10.1093\/ejcts\/ezac209"},{"key":"10.3238\/arztebl.m2025.0211_ref16","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al.: 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44: 3720–826."},{"key":"10.3238\/arztebl.m2025.0211_ref17","unstructured":"Meinel TR, Branca M, De Marchis GM, et al.: Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol 2021; 89: 42–53."},{"key":"10.3238\/arztebl.m2025.0211_ref18","doi-asserted-by":"crossref","unstructured":"Oldgren J, Asberg S, Hijazi Z, et al.: Early versus delayed non-vitamin K Antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): A registry-based randomized controlled noninferiority study. Circulation 2022; 146: 1056–66.","DOI":"10.1161\/CIRCULATIONAHA.122.060666"},{"key":"10.3238\/arztebl.m2025.0211_ref19","unstructured":"Fischer U, Koga M, Strbian D, et al.: Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med 2023; 388: 2411–21."},{"key":"10.3238\/arztebl.m2025.0211_ref20","unstructured":"Werring DJ, Dehbi HM, Ahmed N, et al.: Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): A multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet 2024: 404; 1731–41."},{"key":"10.3238\/arztebl.m2025.0211_ref21","doi-asserted-by":"crossref","unstructured":"Warach SJ, Davis LA, Lawrence P, et al.: Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation: A pragmatic, response-adaptive randomized clinical trial. JAMA Neurol 2025; 82: 470–6.","DOI":"10.1001\/jamaneurol.2025.0285"},{"key":"10.3238\/arztebl.m2025.0211_ref22","unstructured":"Veltkamp R, Korompoki E, Harvey KH, et al.: Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): A multicentre, open-label, randomised, phase 3 trial. Lancet 2025; 405: 927–36."},{"key":"10.3238\/arztebl.m2025.0211_ref23","doi-asserted-by":"crossref","unstructured":"Qureshi AI, Mendelow AD, Hanley DF: Intracerebral haemorrhage. Lancet 2009; 373: 1632–44.","DOI":"10.1016\/S0140-6736(09)60371-8"},{"key":"10.3238\/arztebl.m2025.0211_ref24","doi-asserted-by":"crossref","unstructured":"Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471–7.","DOI":"10.1161\/01.STR.26.8.1471"},{"key":"10.3238\/arztebl.m2025.0211_ref25","doi-asserted-by":"crossref","unstructured":"Biffi A, Kuramatsu JB, Leasure A, et al.: Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol 2017; 82: 755–65.","DOI":"10.1002\/ana.25079"},{"key":"10.3238\/arztebl.m2025.0211_ref26","doi-asserted-by":"crossref","unstructured":"Murthy SB, Gupta A, Merkler AE, et al.: Restarting anticoagulant therapy after intracranial hemorrhage: A systematic review and meta-analysis. Stroke 2017; 48: 1594–600.","DOI":"10.1161\/STROKEAHA.116.016327"},{"key":"10.3238\/arztebl.m2025.0211_ref27","unstructured":"Schreuder F, van Nieuwenhuizen KM, Hofmeijer J, et al.: Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): A randomised, open-label, phase 2 trial. Lancet Neurol 2021; 20: 907–16."},{"key":"10.3238\/arztebl.m2025.0211_ref28","unstructured":"So SC: Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: A randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol 2021; 20: 842–53."},{"key":"10.3238\/arztebl.m2025.0211_ref29","doi-asserted-by":"crossref","unstructured":"Morotti A, Boulouis G, Dowlatshahi D, et al.: Intracerebral haemorrhage expansion: Definitions, predictors, and prevention. Lancet Neurol 2023; 22: 159–71.","DOI":"10.1016\/S1474-4422(22)00338-6"},{"key":"10.3238\/arztebl.m2025.0211_ref30","doi-asserted-by":"crossref","unstructured":"Blackshear JL, Odell JA: Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755–9.","DOI":"10.1016\/0003-4975(95)00887-X"},{"key":"10.3238\/arztebl.m2025.0211_ref31","doi-asserted-by":"crossref","unstructured":"Rauhala M, Luoto TM, Huhtala H, et al.: The incidence of chronic subdural hematomas from 1990 to 2015 in a defined Finnish population. J Neurosurg 2020; 132: 1147–57.","DOI":"10.3171\/2018.12.JNS183035"},{"key":"10.3238\/arztebl.m2025.0211_ref32","doi-asserted-by":"crossref","unstructured":"Tommiska P, Knuutinen O, Lonnrot K, Kivisaari R, Raj R, group Fs: Association between postoperative thromboembolic and hemorrhagic complications and clinical outcomes after surgery for chronic subdural hematoma in patients with anticoagulation therapy for atrial fibrillation. Acta Neurochir (Wien) 2025; 167: 17.","DOI":"10.1007\/s00701-025-06728-9"},{"key":"10.3238\/arztebl.m2025.0211_ref33","doi-asserted-by":"crossref","unstructured":"Anno T, Fukasawa T, Shinozaki T, Takeuchi M, Yoshida S, Kawakami K: Impact of early resumption of oral anticoagulation on recurrence after surgery for chronic subdural hematoma in patients with atrial fibrillation: A target trial emulation. Pharmacoepidemiol Drug Saf 2024; 33: e70063.","DOI":"10.1002\/pds.70063"},{"key":"10.3238\/arztebl.m2025.0211_ref34","unstructured":"Davies JM, Knopman J, Mokin M, et al.: Adjunctive middle meningeal artery embolization for subdural hematoma. N Engl J Med 2024; 391: 1890–900."},{"key":"10.3238\/arztebl.m2025.0211_ref35","doi-asserted-by":"crossref","unstructured":"Tarlov N, Norbash AM, Nguyen TN: The safety of anticoagulation in patients with intracranial aneurysms. J Neurointerv Surg 2013; 5: 405–9.","DOI":"10.1136\/neurintsurg-2012-010359"},{"key":"10.3238\/arztebl.m2025.0211_ref36","doi-asserted-by":"crossref","unstructured":"Zuurbier SM, Hickman CR, Tolias CS, et al.: Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: A population-based cohort study, systematic review, and meta-analysis. Lancet Neurol 2019; 18: 935–41.","DOI":"10.1016\/S1474-4422(19)30231-5"},{"key":"10.3238\/arztebl.m2025.0211_ref37","doi-asserted-by":"crossref","unstructured":"Steffel J, Heidbuchel H: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Comment-authors‘ reply. Europace 2021; 23: 1685–6.","DOI":"10.1093\/europace\/euab218"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:13:28Z","timestamp":1774340008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":37,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0211","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]}}}